Clinical Trial Update: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

NiKang Therapeutics is conducting a Phase 1 study of NKT3964 in adults with advanced or metastatic solid tumors, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Gastric Cancer
• Ovarian Cancer
• Platinum-resistant Ovarian Cancer
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• NKT3964

Snippet

Sponsor: NiKang Therapeutics, Inc. | Conditions: Solid Tumor, Advanced Solid Tumor | Phase 1 | Status: RECRUITING